Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes
• Treatments: Anesthetics; Remifentanil

Criteria

Inclusion Criteria:

• Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux

• Patient able to give informed consent, and sign the consent.

Exclusion Criteria:

• Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction

• Morbid obesity (Body Mass Index > 40)

• Emergency situation with unstable hemodynamics, and stabilization is impossible before induction

• Inclusion in another research project within the past 3 months

• The patient is not insured or beneficiary of a health insurance plan (for the French centers)

• Patient under guardianship of any kind

• Patient unable to give informed consent

• Refusal to sign the consent form